Abstract:INTRODUCTION: Galectin-3 (Gal-3), a lectin with preference for β-galactoside-containing carbohydrates, is a structurally unique member of the galectin family. It is ubiquitously expressed in various mammalian tissues with a wide distribution from the intracellular environment to the extracellular space. Gal-3 is a well-established player in numerous diseases, from infections to heart failure. Notably, as Gal-3 overexpression is associated with cancer drug resistance, it has been identified as a valuable therapeutic target in the fight against cancers.AREAS COVERED: This review discusses the recent progress of patent applications (2008-present) and the current knowledge of pertinent Gal-3-inhibitor interactions in an effort to progress the development of selective and high affinity carbohydrate-based inhibitors targeting Gal-3, with an emphasis on engaging a structure-based drug design rationale.EXPERT OPINION: The lack of commercially available anti-Gal-3 therapeutic reagents and its clear involvement in serious disease, notably cancer, leads to an urgent need for development of inhibitors that specifically target Gal-3. Design of potent and selective carbohydrate inhibitors targeting Gal-3 is challenging due to relative weak protein-carbohydrate interactions along with the high sequence homology in the carbohydrate binding site region among galectins. To date, some chemical scaffolds have been exploited for design of promising effective Gal-3 inhibitors for cancer therapy.

Structure, Function and Therapeutic Inhibitors"

Dissecting the Structure–Activity Relationship of Galectin–Ligand Interactions

Inhibition of Galectins with Small Molecules

Glycomimetic inhibitors of tandem-repeat galectins: Simple and efficient

Galectin–Carbohydrate Interactions in Biomedicine and Biotechnology

Intracellular galectin interactions in health and disease

Protein glycosylation. Structural and functional aspects

Altering the Modular Architecture of Galectins Affects its Binding with Synthetic α-Dystroglycan O-Mannosylated Core M1 Glycoconjugates In situ

Galactose: A Versatile Vector Unveiling the Potentials in Drug Delivery, Diagnostics, and Theranostics

An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016–present)

Galectin-1: A Traditionally Immunosuppressive Protein Displays Context-Dependent Capacities

Galectins in epithelial-mesenchymal transition: roles and mechanisms contributing to tissue repair, fibrosis and cancer metastasis

Emerging role of galectin family in inflammatory autoimmune diseases

The interplay of galectins-1, -3, and -9 in the immune-inflammatory response underlying cardiovascular and metabolic disease

Galectin-3 inhibitors: a patent review (2008–present)

Exploration into Galectin-3 Driven Endocytosis and Lattices

New clues arising from hunt of saccharides binding to galectin 3 via 3D QSAR and docking studies

Biophysical and Structural Characterization of the Interaction between Human Galectin-3 and the Lipopolysaccharide from Pseudomonas aeruginosa

Small lectin ligands as a basis for applications in glycoscience and glycomedicine

Current Status on Therapeutic Molecules Targeting Siglec Receptors

Synthetic glycoconjugates inhibitors of tumor-related galectin-3: an update